The useful thing about a blind spot is that someone standing elsewhere may see a market in it. Seae Ventures was formed around that premise. Its founders had spent years inside healthcare and its investment machinery, including Blue Cross Blue Shield of Massachusetts and the insurer's venture arm, Zaffre Investments. They knew how a promising health product could vanish between a pilot, a reimbursement code, a procurement committee and a patient who never had reliable access in the first place. They had also watched capital flow through networks that did not consistently reach women and founders of color.
In 2019, Jason Robart, Tuoyo Louis and Pete Sally left that corporate vantage point and started an independent firm. A wonderfully unglamorous detail survives from the origin story: Seae began in the basement of the Boston Public Library. The setting fits. This was less a garage myth than a research project with consequences - three operators comparing what the healthcare system claimed to need with what venture capital was prepared to fund.
Today Seae invests in early-stage healthcare technology and services, with a smaller financial-wellness thread. The firm reports 40 portfolio companies. Its roster ranges from Tia's hybrid women's healthcare and FOLX Health's virtual care for LGBTQIA+ adults to MD Ally's 911 navigation, Movn Health's virtual cardiac rehabilitation and Cayaba Care's community-based maternity support. These companies sell different things to different buyers. Their common feature is friction: each is trying to make a stubborn part of American care easier to reach, deliver, understand or pay for.
01 / The double blind spot
Equity is not a side pocket
Many investment firms describe underserved groups as an impact allocation sitting beside the main business. Seae's thesis is more structural. When geography, income, race or gender makes care harder to obtain, that failure also reveals unserved demand. The founder who has lived near the problem may understand its workflow, trust barrier and buyer better than an outsider with a prettier pitch deck. In this view, widening the founder funnel is not charity. It is a method for finding information the established network failed to collect.
The portfolio numbers make the argument concrete. Seae says 40 percent of its companies serve Medicaid populations and one-third focus primarily on women's health. Across the portfolio, companies reach 85 million covered lives and process $200 billion in claims each year. Those figures do not prove investment returns. They do show that the thesis is aimed at large, operational parts of healthcare rather than a collection of boutique wellness apps.
“We seek out those founders who haven't had traditional access to capital.”Erica Murdock · Managing Partner
That sentence contains both halves of the model. Seae looks for founders who know a neglected market, then tries to give them the kind of industry access that conventional founders often inherit through their networks. The firm is explicit about backing women and Black, Indigenous and other people of color, but the commercial screen remains healthcare-scale: clinical evidence, a credible buyer, workable economics and the ability to move through regulation and reimbursement.
02 / What the firm sells
A check, a translator and a route through procurement
Venture firms do not make products in the usual sense. Seae manages private funds, selects equity investments and supports the companies after the check. Limited partners supply the capital and seek returns; founders receive financing and help building their businesses. Management fees and a share of investment gains are the familiar economics. What differentiates one fund from another is the quality of its judgment and the usefulness of its network.
Seae's network was designed around healthcare's unusually complicated buying system. Its first $107 million fund drew more than 30 investors, including health plans, the American Hospital Association, Eli Lilly, Goldman Sachs, foundations and financial institutions. Several are not passive names on a slide. Health plans can explain what a payer will reimburse, what evidence it expects and why a product that delights a patient might still fail a budget review. Providers can expose where a tool adds one more click to a clinician's day. Clinical advisers can ask whether the evidence survives contact with a real patient population.
The practical value is translation. A founder may know precisely why a community avoids a clinic but not how to sell into a national payer. An insurer may understand its claims data but not the daily experience behind a missed appointment. Seae sits between them, trying to turn one side's knowledge into a product the other side can buy. This is useful to entrepreneurs building in maternal health, behavioral health, value-based care, diagnostics, clinical AI and the administrative plumbing beneath them.
03 / The portfolio map
Follow the cost, then look upstream
Seae organizes its public thesis around four failures. The first is overspending on acute care while underinvesting in prevention, primary care and behavioral health. The second is the expensive separation of medical and behavioral care. The third is access at the wrong place or time, which sends solvable needs into emergency departments and 911 systems. The fourth is fragile infrastructure at safety-net and community providers, where old workflows and thin margins make innovation difficult.
This framework helps explain the apparent variety. MD Ally diverts appropriate non-emergency calls toward virtual care. Cayaba Care adds maternity navigators who can help with clinical, behavioral and social needs. Iterative Health applies computer vision and data to gastroenterology research and care. Tia combines primary, reproductive and behavioral services for women. FOLX builds affirming virtual care for LGBTQIA+ adults. The products differ, but each tackles a handoff where the system loses time, money or trust.
Seae's 2023 partnership with East Boston Neighborhood Health Center, now NeighborHealth, made the model unusually tangible. Portfolio companies gained a channel for learning from a safety-net provider serving a largely Hispanic population. The point was not to drop technology into a community and call it access. It was to understand the social and clinical conditions that determine whether technology gets used.
04 / The Unseen chapter
An acquisition with a memory
In July 2024, Seae acquired Unseen Capital, the healthcare fund created by the late Kayode Owens. Unseen had backed founders intimately familiar with challenges facing marginalized communities. The deal took Seae's reported assets under management above $200 million at the time and gave it a dedicated pre-seed and early-seed platform. It also created a delicate obligation: integrate the companies without sanding away the purpose that made the fund worth acquiring.
Seae kept the Unseen name in its portfolio architecture, put healthcare operator and founder Erica Murdock in charge of the strategy, and announced a fellowship and HBCU scholarship effort honoring Owens. Eli Lilly, an early investor in Unseen as well as an investor in Seae's funds, remained part of the relationship. The result is a broader ladder: Unseen can meet a company before conventional metrics appear, while Seae's main funds can support businesses as they mature.
“Access creates opportunity. Opportunity creates equity.”Seae Ventures
05 / Where Seae fits
Specialist capital in a market that punishes tourists
Seae occupies an overlap among digital-health investing, healthcare services, fintech and impact-oriented venture capital. Rock Health Capital, Town Hall Ventures, HealthQuest, 7wireVentures and Define Ventures compete for portions of the same healthtech deal flow. Jumpstart Nova, SteelSky Ventures, Kapor Capital and Impact Engine overlap more directly with parts of its health-equity or founder-access thesis. Founders can also choose generalist funds with larger platforms, strategic corporate investors or health-system venture arms.
Seae's distinction is the combination: former payer operators, a limited-partner base rich in healthcare buyers, a clinical advisory council, an early-stage focus and an explicit search for founders outside traditional networks. None is unique alone. Together they create a diligence machine tuned to questions generalist investors can underestimate: Who gets reimbursed? Which clinician owns the workflow? Does the product work for Medicaid? Can a community trust it? What looks like a small market only because the old system never measured the people in it?
There are limits to the model. Strategic LPs can open doors but cannot manufacture product-market fit. Social purpose does not spare a startup from healthcare's long sales cycles. Portfolio reach is not the same as patient outcome, and assets under management are not investment performance. Seae's case ultimately rests on returns that private funds disclose selectively. The firm must prove that its expanded funnel produces durable companies, not merely a more representative collection of pitch decks.
Still, the operating logic is clear. The American healthcare market spends heavily on failures it has normalized: avoidable emergency use, disconnected behavioral care, clinician administration, poor maternal outcomes and entire communities navigating care without a reliable front door. Entrepreneurs close to those failures often know where the workaround begins. Seae's job is to decide which workaround can become infrastructure.
The firm says it closed Fund II in 2026 with returning and new limited partners, though it has not published the final amount on its website. That new capital arrives as digital health grows more sober about what survives after novelty. In that market, Seae's operator instincts may matter more than its rhetoric. A health company needs someone who can recognize both an unmet human need and the budget line capable of paying for it.
That is the stealable idea in Seae's story: look for two systems failing in the same place. One system failed to serve certain patients. Another failed to fund many of the founders who understood those patients. Connecting the two does not guarantee a great company. It does create a more interesting place to search.